Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AmericanWarner Nutritionals Would Have Research, Money, Marketing Savvy

This article was originally published in The Tan Sheet

Executive Summary

The planned union of American Home Products and Warner-Lambert would create a formidable presence in the dietary supplement and nutritionals marketplace, with established and well-backed brands in the vitamins, herbals and hybrid OTC segments.

You may also be interested in...



AmericanWarner Would House Nearly $5 Bil. Consumer Health Unit

Warner-Lambert's consumer products/OTC business would have a more natural home with American Home Products than with Pfizer.

AmericanWarner Would House Nearly $5 Bil. Consumer Health Unit

Warner-Lambert's consumer products/OTC business would have a more natural home with American Home Products than with Pfizer.

AmericanWarner Would House Nearly $5 Bil. Consumer Health Unit

Warner-Lambert's consumer products/OTC business would have a more natural home with American Home Products than with Pfizer.

Related Content

Topics

UsernamePublicRestriction

Register

PS090523

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel